Albert M, Mairet-Coello G, Danis C, Lieger S, Caillierez R, Carrier S, Skrobala E, Landrieu I, Michel A, Schmitt M, Citron M, Downey P, Courade JP, Buée L, Colin M (2019) Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain 142(6):1736–1750. https://doi.org/10.1093/brain/awz100

Article  PubMed  PubMed Central  Google Scholar 

Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, Walz T, Pepinsky RB, Bussière T, Hamann S, Cameron TO, Weinreb PH (2018) Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep 8(1):6412. https://doi.org/10.1038/s41598-018-24501-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asher S, Priefer R (2022) Alzheimer’s disease failed clinical trials. Life Sci 306:120861. https://doi.org/10.1016/j.lfs.2022.120861

Article  CAS  PubMed  Google Scholar 

Athar T, Balushi KA, Khan SA (2021) Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease. Mol Biol Rep 48:5629–5645. https://doi.org/10.1007/s11033-021-06512-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bayer TA (2022) Pyroglutamate Aβ cascade as drug target in alzheimer’s disease. Mol Psychiatry 27(4):1880–1885. https://doi.org/10.1038/s41380-021-01409-2

Article  CAS  PubMed  Google Scholar 

Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer OK, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H (2012) Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cellmediated removal of human amyloid-β. J Alzheimers Dis 28(1):49–69. https://doi.org/10.3233/JAD-2011-110977

Article  CAS  PubMed  Google Scholar 

Boyarko B, Podvin S, Greenberg B, Momper JD, Huang Y, Gerwick WH, Bang AG, Quinti L, Griciuc A, Kim DY, Tanzi RE, Feldman HH, Hook V (2023) Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease. Front Pharmacol 4:1190402. https://doi.org/10.3389/fphar.2023.1190402

Article  CAS  Google Scholar 

Bright J, Hussain S, Dang V, Wright S, Cooper B, Byun T, Ramos C, Singh A, Parry G, Stagliano N, Griswold-Prenner I (2015) Human secreted tau increases amyloid-beta production. Neurobiol Aging 36(2):693–709. https://doi.org/10.1016/j.neurobiolaging.2014.09.007

Article  CAS  PubMed  Google Scholar 

Burki T (2018) Alzheimer’s disease research: the future of BACE inhibitors. Lancet 391:2486. https://doi.org/10.1016/S0140-6736(18)31425-9

Article  PubMed  Google Scholar 

Byung WK, Ashish K, Dong-Keun S, Jae-Young H, Jai JC (2023) Protective effects of AR1001 in Alzheimer’s disease models: polypharmacological mechanisms. Alzheimers Dement 19(Suppl. 24):e082892. https://doi.org/10.1002/alz.082892

Article  Google Scholar 

Cheng F, Hernandez P, Liow L, Damiano E, Zetterberg H, Blennow K, Feng D, Chen M, Maccecchini M (2023) Buntanetap, a novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and promising in both Alzheimer’s and Parkinson’s patients. J Prev Alzheimers Dis 10:25–33. https://doi.org/10.14283/jpad.2022.84

Article  Google Scholar 

Coman H, Nemeş B (2017) New therapeutic targets in Alzheimer’s disease. Int J Gerontol 11:2–6. https://doi.org/10.1016/j.ijge.2016.07.003

Article  Google Scholar 

Cummings JL, Osse AML, Kinney JW (2023) Alzheimer’s disease: novel targets and investigational drugs for disease modification. Drugs 83:1387–1408. https://doi.org/10.1007/s40265-023-01938-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F (2024a) Alzheimer’s disease drug development pipeline: 2024. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. https://doi.org/10.1002/trc2.12465

Article  Google Scholar 

Cummings J, Osse AML, Cammann D, Powell J, Chen J (2024b) Anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s Disease. Biodrugs 38(1):5–22. https://doi.org/10.1007/s40259-023-00633-2

Article  CAS  PubMed  Google Scholar 

Davidowitz EJ, Lopez P, Jimenez H, Adrien L, Davies P, Moe JG (2023) Small molecule inhibitor of tau self-association in a mouse model of tauopathy: a preventive study in P301L tau JNPL3 mice. PLoS One 18(8):e0286523. https://doi.org/10.1371/journal.pone.0286523

Article  CAS  PubMed  PubMed Central  Google Scholar 

DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, Zanardi TA, Kordasiewicz HB, Swayze EE, Bennett CF, Diamond MI, Miller TM (2017) Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med 9(374):25–14. https://doi.org/10.1126/scitranslmed.aag0481

Article  CAS  Google Scholar 

Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, Hermine O, Tsolaki M (2023) Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimers Res Ther 28(1):39. https://doi.org/10.1186/s13195-023-01169-x

Article  CAS  Google Scholar 

Feldman HH, Messer K, Qiu Y, Sabbagh M, Galasko D, Turner RS, Lopez O, Smith A, Durant J, Lupo JL, Revta C, Balasubramanian A, Kuehn-Wache K, Wassmann T, Schell-Mader S, Jacobs DM, Salmon DP, Léger G, DeMarco ML, Weber F, ADCS VIVA-MIND Study Group (2024) Varoglutamstat: inhibiting glutaminyl cyclase as a novel target of therapy in early Alzheimer’s disease. J Alzheimers Dis 101(s1):S79–S93

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galpern WR, Triana-Baltzer G, Li L, Van Kolen K, Timmers M, Haeverans K, Janssens L, Kolb H, Nandy P, Aida K, Shimizu H, Mercken M, Sun H (2024) Phase 1 studies of the anti-Tau monoclonal antibody JNJ-63733657 in healthy participants and participants with Alzheimer’s disease. J Prev Alzheimers Dis 11(6):1592–1603. https://doi.org/10.14283/jpad.2024.163

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerson DH, Roberta DB (2022) Allopregnanolone: regenerative therapeutic to restore neurological health. Neuro Stress 21:100502. https://doi.org/10.1016/j.ynstr.2022.100502

Article  CAS  Google Scholar 

Hernandez GD, Solinsky CM, Mack WJ, Kono N, Rodgers KE, Wu CY, Mollo AR, Lopez CM, Pawluczyk S, Bauer G, Matthews D, Shi Y, Law M, Rogawski MA, Schneider LS, Brinton RD (2020) Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer’s disease: a single and multiple ascending dose phase 1b/2a clinical trial. Alzheimers Dement 16(1):e12107. https://doi.org/10.1002/trc2.12107

Article  Google Scholar 

Hovakimyan A, Chilingaryan G, King O, Capocchi JK, Chadarevian JP, Davtyan H, Kniazev R, Agadjanyan MG, Ghochikyan A (2024) mRNA Vaccine for Alzheimer’s Disease: Pilot Study. Vaccines (Basel) 12(659):1–15. https://doi.org/10.3390/vaccines12060659

Article  CAS  Google Scholar 

Huang LK, Kuan YC, Lin HW, Hu CJ (2023) Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update. J Biomed Sci 30:1–19. https://doi.org/10.1186/s12929-023-00976-6

Article  CAS  Google Scholar 

Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, Grundman M, Schneider LS, DeKosky ST, Chelsky D, Pike I, Henstridge C, Blennow K, Zetterberg H, LeVine H 3rd, Spires-Jones TL, Cirrito JR, Catalano SM (2021) Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer’s disease modification. Alzheimers Dement 17:1365–1382. https://doi.org/10.1002/alz.12302

Johansson JO, Winblad B, Michaelson DM, Zetterberg H, Cummings JL, Yassine HN (2025) The ABCA1 agonist CS6253 shows favourable safety and pharmacokinetics in IND‐enabling toxicology and phase 1 human studies aimed at the indication of Alzheimer’s disease. Alzheimers Dement 9(Suppl 6):e091450. https://doi.org/10.1002/alz.091450

Article  Google Scholar 

Khartabil N, Awaness A (2025) Targeting amyloid pathology in early Alzheimer’s: the promise of Donanemab-Azbt. Pharmacy 13(1):23. https://doi.org/10.3390/pharmacy13010023

Article  PubMed  PubMed Central  Google Scholar 

Kuti B, Alexander K (2022) IBC-Ab002, an anti-PD-L1 monoclonal antibody tailored fortreating Alzheimer’s disease. Alzheimer & Dementia. The journal of the Alzheimer Association.1–2: https://doi.org/10.1002/alz.042978

Kutzsche J, Jürgens D, Willuweit A, Adermann K, Fuchs C, Simons S, Windisch M, Hümpel M, Rossberg W, Wolzt M, Willbold D (2020) Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: a single and multiple ascending dose phase I study. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 6:e12001. https://doi.org/10.1002/trc2.12001

Article  Google Scholar 

Long H, Simmons A, Mayorga A (2024) Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease. Alz Res Therapy 16(235):1–19. https://doi.org/10.1186/s13195-024-01599-1

Article  CAS